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Abstract: Meyer-Rath and Over assert in another article
in the July 2012 PLoS Medicine Collection, ‘‘Investigating
the Impact of Treatment on New HIV Infections’’, that
economic evaluations of antiretroviral therapy (ART) in
currently existing programs and in HIV treatment as
prevention (TasP) programs should use cost functions that
capture cost dependence on a number of factors, such as
scale and scope of delivery, health states, ART regimens,
health workers’ experience, patients’ time on treatment,
and the distribution of delivery across public and private
sectors. We argue that for particular evaluation purposes
(e.g., to establish the social value of TasP) and from
particular perspectives (e.g., national health policy mak-
ers) less detailed cost functions may be sufficient. We then
extend the discussion of economic evaluation of TasP,
describing why ART outcomes and costs assessed in
currently existing programs are unlikely to be generaliz-
able to TasP programs for several fundamental reasons.
First, to achieve frequent, widespread HIV testing and
high uptake of ART immediately following an HIV
diagnosis, TasP programs will require components that
are not present in current ART programs and whose costs
are not included in current estimates. Second, the early
initiation of ART under TasP will change not only patients’
disease courses and treatment experiences—which can
affect behaviors that determine clinical treatment success,
such as ART adherence and retention—but also quality of
life and economic outcomes for HIV-infected individuals.
Third, the preventive effects of TasP are likely to alter the
composition of the HIV-infected population over time,
changing its biological and behavioral characteristics and
leading to different costs and outcomes for ART.
More versus Less Detailed Cost Functions
The results from the HTPN 052 trial reported in August 2011
demonstrated under the controlled conditions of a well-conducted
clinical trial that early antiretroviral therapy (ART) can be highly
effective in preventing transmission of HIV in stable heterosexual
HIV-discordant couples [1]. Several experimental studies are
currently underway or planned to investigate the effectiveness of
HIV treatment as prevention (TasP) in general populations,
including in HIV hyperendemic communities in sub-Saharan
Africa [2,3]. A few mathematical modeling studies have predicted
the cost-effectiveness of TasP, using cost estimates derived from
currently existing ART programs [4–7]. Meyer-Rath and Over
review prior studies of ART costs, and discuss the cost assumptions
used in economic evaluations of HIV treatment [8]. They find that
economic evaluations of TasP have tended toward a simplified
accounting for variation in ART costs across patients and settings,
focusing on a limited set of factors such as regimen or disease
stage. Meyer-Rath and Over argue that future economic
evaluation should account for a range of other factors that may
be significant determinants of ART costs, including scale and
scope of delivery, health states, ART regimens, health workers’
experience, patients’ time on treatment, and the distribution of
delivery across public and private sectors.
In making this argument, Meyer-Rath and Over distinguish
between two categories of ART cost functions [8]: ‘‘cost
accounting identities,’’ which generate estimates of total costs
based on mathematical representations of the production process,
and ‘‘flexible cost functions,’’ which generate estimates of total
costs based on empirically derived relationships between costs and
other factors, while treating the details of the production process as
a ‘‘black box’’ (Text S1 of [8]). Meyer-Rath and Over find that
that ‘‘[m]ost existing [ART] cost projections assume a single
constant unit cost per patient-year, or per patient-year on a certain
regimen,’’ while a few have allowed for variation of costs by
disease stage but not by other factors [8]. Concerns with the level
of detail in modeling the costs of TasP derive in part from the past
focus on predictive, or ex ante, economic evaluations, which rely
heavily on mathematical or statistical models to extrapolate from
limited empirical observations (as opposed to ex post evaluations,
which use direct observation of actual costs and benefits) [9].
It may indeed be ideal to capture the dependence of costs on
many factors in economic evaluation of TasP—a task that could
theoretically be achieved either by improving our understanding of
the production process or through empirical examination of
relationships between costs and other factors. However, the
necessary data on the ART production process or on the
relationship between ART costs and factors such as the scope of
delivery or patients’ time on treatment are currently largely lacking
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future, despite ongoing studies that will generate such data for a
few settings. The absence of empirical data raises the question
whether economic evaluation of TasP can be ‘‘good enough’’
without accounting for the dependence of ART costs on many of
the factors that Meyer-Rath and Over argue convincingly could be
determinants of ART costs.
The answer to this question will depend on both evaluation
purpose and perspective. If the purpose is to decide whether or not
to implement TasP, less detailed cost functions may be sufficient,
because the result will be a yes/no answer indicating whether
TasP produces a net benefit to society, or falls below some
predetermined cost-effectiveness threshold. Such a result may be
relatively robust to imprecision in the specification and estimation
of costs. If, on the other hand, the purpose of the evaluation is to
establish the most efficient approach to deliver TasP, given that it
has been decided that it should be implemented, it will be crucial
for the analysis to capture cost variations based on factors such as
health worker–to–patient ratio, size and type of health care facility,
and the level of integration of TasP programs into the general
health care system.
The example Meyer-Rath and Over calculate in their article is a
case in point. Based on theoretical considerations of economies of
scale and empirical observation of scale effects in most industries,
including in the delivery of HIV prevention services [10–12], they
argue that it is unlikely that average costs would remain constant
across scale of ART delivery. To demonstrate the potential impact
of scale effects on costs, they adjust the estimates for implementing
TasP in South Africa produced by Granich et al. [13] ‘‘for scale
and a plausible pattern of distribution of patients into clinics’’ [8].
The result of this adjustment is an increase in total accumulated
cost over 40 years from US$75 billion to US$106 billion. While
this difference in cost estimates is large, given the dramatic effect of
TasP estimated by Granich et al. [13], it may not alter the overall
conclusion that TasP is a socially worthwhile intervention. In
particular, if TasP could indeed eliminate HIV incidence, as
Granich et al. [13] assert based on their modeling results, the
economic case for TasP would likely be robust to large increases in
the cost estimates. At the same time, cost increases of the
magnitude calculated by Meyer-Rath and Over would be
extremely important for the practical exercises of financial
planning and budgeting for TasP.
Whether less detailed cost functions will suffice in a given
situation is also affected by the evaluation perspective. For
instance, from the perspective of national health policy makers,
economic evaluation may not need to account for the relationship
between ART costs and the sector of delivery because policy
makers may not be concerned about patients who utilize ART in
the private sector. Conversely, from the perspective of for-profit
companies providing ART in workplace HIV treatment programs,
only the private sector costs will be relevant. In such cases, cost
functions that account for differences in public versus private
sector costs are not required.
Meyer-Rath and Over start the important discussion of which
factors to include in cost functions in economic evaluations of
TasP. We argue that for particular evaluation purposes (e.g., to
establish the social value of TasP) and from particular perspectives
(e.g., national health policy makers) ‘‘undetailed’’ cost functions,
which do not capture cost dependence on many factors, may be
sufficient.
ART and TasP Programs: Important
Considerations for Economic Evaluation
A more fundamental issue in the economic evaluation of TasP is
the fact that TasP programs will differ from existing ART
programs in several important respects, which may substantially
impact the costs, outcomes, and cost-effectiveness of TasP (for an
overview, see Table 1).
Program Components and Costs
As Meyer-Rath and Over observe, estimates of ART costs in
models predicting the cost-effectiveness of TasP are usually based
on the mix of interventions in currently existing ART programs.
However, TasP strategies will likely require interventions that are
not usually present in existing ART programs [14]. The costs of
these interventions need to be accounted for in economic
evaluations of TasP. As data on CD4 count at ART initiation
demonstrate [15,16], most HIV-infected people in sub-Saharan
Africa do not start treatment until they have reached advanced
stages of HIV disease (despite a moderate but steady increase in
median CD4 count at initiation over the past years [16]). The late
ART initiation occurs despite national treatment guidelines in sub-
Saharan Africa stipulating that all HIV-positive individuals be
Table 1. Overview of differences between existing ART programs and TasP.
Difference Explanation
Program components To achieve widespread and frequent HIV testing and high uptake of ART immediately following an HIV diagnosis, TasP strategies will
likely require interventions that are not present in current ART programs.
Disease experiences and
treatment outcomes
Disease experiences and treatment-relevant behaviors: patients who initiate ART early are less likely to experience recovery from the
symptoms of the later stages of HIV disease. Lack of such experience may affect behaviors that are crucial for treatment outcomes,
such as ART retention and adherence.
Quality of life: early initiation may reduce quality of life (because it increases the duration of drug side effects and transforms people
into patients several years earlier than under current ART guidelines) or improve quality of life (because it decreases the severity of
drug side effects and avoids the psychologically distressing situation of having to wait for one’s health status to deteriorate before
being allowed to start ART).
Economic productivity: early initiation may reduce the lifetime economic productivity of HIV-infected individuals (because it increases
the total portion of lifetime spent utilizing ART) or improve productivity (because it avoids the negative economic consequences of
deteriorating health preceding late ART initiation).
Patient population In the long run, successful TasP could lead to changes in the composition of the people requiring ART, because the preventive effects
of TasP may benefit some population subgroups at risk of HIV acquisition, but not others.
doi:10.1371/journal.pmed.1001263.t001
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positive HIV test result [17].
To succeed in reducing HIV incidence in the general
population, TasP programs require that very high proportions of
all HIV-infected people in a community receive ART. To this end,
TasP programs must ensure that most community members who
have not been diagnosed with HIV frequently test for HIV and, if
found to be HIV-infected, initiate treatment soon after diagnosis.
The costs of interventions to achieve frequent, widespread HIV
testing (e.g., through community mobilization and home-based
testing) and high uptake of ART among people newly diagnosed
with HIV (e.g., through counseling, improved transport, and
financial incentives) must be included on the cost side of the
economic evaluation of TasP [18].
In addition, some structures and processes that are in place in
existing ART programs may need to be enhanced to achieve good
TasP outcomes, e.g., community-based treatment supporters or
mobile-phone short messages to ensure good ART retention and
adherence [19]. The expenditures for such enhancements need to
be accounted for in the economic evaluation of TasP. Of course,
the specific components required for successful TasP will depend
on the particular TasP intervention strategy—universal popula-
tion-wide HIV testing and treatment will use different approaches,
and incur different costs, than TasP strategies targeted at people at
high risk of HIV transmission, such as HIV-infected individuals in
HIV-discordant couples [2,13,20]. It will thus be crucial that TasP
implementations both in trials and in routine settings are
accompanied by rigorous empirical studies that measure the
expenditures for all TasP components.
Disease Experiences and Treatment Outcomes
A second issue in predicting the cost-effectiveness of TasP based
on costs and outcomes observed in current ART programs is that
TasP patients are initiated earlier on ART than patients in existing
programs. While patients in sub-Saharan Africa currently initiate
ART at a median CD4 cell count below 140 cells/ml [15] (which is
substantially lower than the typical CD4 count eligibility
thresholds of 200 cells/ml or 350 cells/ml), patients in successful
TasP programs would initiate ART soon after first diagnosis of
HIV infection (which ideally would occur soon after HIV
infection). As a result of earlier ART initiation, patients’ disease
experiences and treatment outcomes are likely to be significantly
altered.
Disease experiences and treatment-relevant
behaviors. Patients who initiate ART early are unlikely to
experience the symptoms of the later stages of HIV disease, as well
as the subsequent recovery on treatment, which many patients
enrolled in currently existing ART programs have experienced.
The recovery on ART from weight loss, physical weakness, and
the opportunistic infections of late-stage HIV disease may
convince patients in current treatment programs that ART is
indeed effective and, as a result, improve their long-term ART
retention and adherence. Patients in successful TasP programs, on
the other hand, will usually lack such experiences and may
consequently be less motivated to adhere well to their clinical
appointments and drug regimens. Rates of resistance develop-
ment, mortality, and morbidity may thus be higher in TasP
programs than in existing ART programs.
Quality of life. TasP is also likely to affect quality of life, but
the direction and magnitude of the net effect over a patient’s life
course is unknown. TasP patients who initiate ART early will
experience drug side effects of ART for a longer total duration
than patients in currently existing programs. At the same time, side
effects and toxicities may be less frequent or less severe in patients
who initiate ART early [21,22], and TasP patients who adhere
well to their treatment regimens may be able to completely avoid
some of the symptoms of more advanced stages of HIV disease
that can substantially reduce quality of life [23]. It is further
plausible that early ART initiation improves quality of life because
it avoids the psychologically distressing situation of having to wait
for one’s health status to deteriorate before being allowed to start
ART. Conversely, it is also plausible that early initiation reduces
quality of life, because it transforms people with no obvious
symptoms into patients, and burdens them with the responsibilities
of chronic disease treatment, such as regular clinic visits and pill-
taking, several years earlier than under current ART guidelines.
Importantly, the net effect of TasP on quality of life will depend
on the counterfactual to which it is compared. Since economic
evaluation is intended to inform the decision whether to
implement TasP against the background of already existing
policies, the best counterfactual will be ART provided at the
current ART eligibility threshold in a country. In particular
settings, such as the US, where individuals are currently already
eligible at the highest CD4 count for which there is clear evidence
of health benefit to the HIV-infected patient [24], TasP will be
equivalent to initiating on ART a group of people who will not yet
derive benefits for their own health from the treatment. In these
situations, limiting the health effects of TasP will be limited to
reduction of HIV transmission to others and quality of life
changes. Empirical evaluations of TasP should thus always include
quality of life assessments.
Economic productivity. In current ART programs, ART
patients’ economic situation commonly improves with time on
treatment [25–27], and recent evidence from a population-based
study shows that ART can lead to nearly full employment recovery
among HIV patients in rural Southern Africa [28]. In the context
of TasP, patients who adhere well to their treatment regimens will
be unlikely to experience negative effects of HIV on economic
productivity because they initiate ART many years before they
would have suffered from significant HIV disease, had they not
received ART. On the other hand, TasP patients will start
incurring the time losses and transport costs of ART utilization
several years earlier in their disease course than patients enrolled
in currently existing ART programs. For economic evaluations
that take the perspective of the society as a whole, which include
patients’ private expenditure and economic productivity in
addition to the costs incurred by the public health care sector,
ART effects on patient income must be incorporated in the
analysis. As the direction and magnitude of TasP effects on
economic outcomes over a patient’s life course are currently
unknown, these effects need to be established in empirical studies
of TasP.
Changes in the HIV-Infected Population
Above, we have argued that the same people would behave
differently in TasP programs than they currently do in existing
ART programs. But, over time, TasP will also change who the
people living with HIV are. One important reason for this change
arises because people who newly acquire HIV despite successful
implementation of TasP in their communities are likely to differ in
their biology or behavior from the people who have acquired HIV
in the past and are currently receiving treatment. If TasP is indeed
effective in averting onward transmission of HIV, the people who
acquire HIV in the presence of TasP may have particularly weak
immune-system functioning or engage in exceptionally high-risk
sexual behavior with HIV-infected people who do not participate
in TasP. Thus, under successful TasP strategies the population of
HIV-infected individuals will not only be smaller (as the TasP
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survival [29,30]), but it will also possess different average
characteristics, e.g., regarding biological susceptibility to HIV
infection or sexual risk-taking. As average ART patient charac-
teristics change following the introduction of TasP, it is likely that
ART costs and outcomes will change as well, because some of the
characteristics that determine the extent to which a person is
protected from HIV acquisition by TasP will also affect ART
success (such as immunological functioning or adherence behav-
ior).
Conclusion
Over the coming years, more detailed cost data are likely to
become available, which will allow incorporating the cost
determinants that Meyer-Rath and Over identify into predictive
models of the economic value of TasP. While these data are not
yet available, it is important to keep in mind that detail in
representing the dependence of ART costs on a range of factors in
economic evaluation is likely to matter far less for establishing
whether TasP is beneficial for a population than for determining
which models of TasP delivery allocate scarce resources optimally.
For the former purpose, relatively simple cost functions may be
sufficient.
Several more fundamental issues deserve consideration in
setting up economic evaluations of TasP. First, to achieve
frequent, widespread HIV testing and high uptake of ART
immediately following an HIV diagnosis, TasP programs will likely
require components that are not present in current ART programs
and whose costs are thus not incorporated in current cost estimates
(such as community mobilization and frequent HIV testing of all
community members who have not been diagnosed with HIV).
Second, the early initiation of ART under TasP will change not
only patients’ disease courses and treatment experiences (which
can affect behaviors that determine clinical treatment success, such
as ART adherence and retention), but also the quality of life and
economic productivity of HIV-infected populations—changes in
outcomes that need to be accounted for in economic evaluation.
And, third, the preventive effects of TasP are likely to alter the
composition of the HIV-infected population in the long run,
changing its biological and behavioral characteristics and leading
to ART costs and outcomes that are different from those observed
for current ART patients.
Hence, while it is useful to predict the economic value of TasP
using data from existing ART programs, such forecasts can only
serve as an initial guide for health policy. Future studies
accompanying ongoing and planned TasP trials and implemen-
tations need to comprehensively assess the costs of all TasP
components, as well as TasP effects on a range of outcomes
beyond HIV incidence and mortality, including quality of life and
economic productivity.
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